Vor Biopharma Inc.
Vor Biopharma Inc. (NASDAQ: VBP) is a clinical-stage biopharmaceutical company focused on developing novel therapies for autoimmune diseases. The company's website is www.vorbiopharma.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Vor Biopharma Inc. does
In the company’s own words
Vor Biopharma Inc. (NASDAQ: VBP) is a clinical-stage biopharmaceutical company focused on developing novel therapies for autoimmune diseases. The company's website is www.vorbiopharma.com.
In June 2025, Vor Biopharma in-licensed telitacicept from RemeGen Co., Ltd., securing exclusive development and commercialization rights outside of Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. Telitacicept is a fusion protein constructed with the extracellular domain of the human TACI receptor and the Fc domain of human IgG. The drug targets two critical cell signaling molecules for B lymphocyte development: BLyS (also known as BAFF) and APRIL, enabling it to reduce B cell-mediated autoimmune responses implicated in several autoimmune diseases.
Telitacicept is already approved in China for systemic lupus erythematosus, rheumatoid arthritis, and generalized myasthenia gravis, with two pending biologics license applications in China for Sjögren's disease and IgA nephropathy. Vor Biopharma is advancing the drug through global Phase 3 clinical trials in generalized myasthenia gravis across the United States, Europe, South America, and Asia, with topline data anticipated in the first half of 2027. The company recently initiated a global Phase 3 trial in Sjögren's disease with first patient dosing in March 2026, also recruiting across multiple regions to support potential approvals in major markets.
The company received Orphan Drug Designation from both the FDA and European Medicines Agency for telitacicept in generalized myasthenia gravis treatment, along with Fast-Track Designation from the FDA for Sjögren's disease. Prior to acquiring telitacicept, Vor Biopharma focused on developing therapies for blood cancers through genetically engineered hematopoietic stem cells. In May 2025, the company announced the winddown of these prior clinical and manufacturing operations, subsequently divesting related intellectual property and license agreements in August and September 2025.
Vor Biopharma plans to build focused commercial capabilities across the United States, South America, Europe, Japan, and the Middle East and North Africa to support potential commercialization of telitacicept if approved. The company relies on third-party contract manufacturers for clinical and commercial manufacturing of required materials and finished products.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1817229
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Vor Biopharma Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Vor Biopharma Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Vor Biopharma Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Vor Biopharma Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Vor Biopharma Inc.'s last four quarterly filings that the numbers alone won't show?”